For the quarter ending 2025-09-30, BRTX has $5,642,662 in assets. $602,444 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 602,444 | 1,555,251 | ||
| Investments held in marketable securities | 3,887,383 | 5,825,685 | ||
| Accounts receivable | 13,400 | 15,000 | ||
| Prepaid expenses and other current assets | 204,237 | 201,871 | ||
| Total current assets | 4,707,464 | 7,597,807 | ||
| Deferred offering costs | 69,066 | 0 | ||
| Property and equipment, net | 309,498 | 339,681 | ||
| Intangible assets, net | 556,634 | 579,071 | ||
| Total assets | 5,642,662 | 8,516,559 | ||
| Accounts payable | 859,898 | 609,931 | ||
| Accrued expenses and other current liabilities | 607,470 | 480,925 | ||
| Warrant liabilities | 1,968,315 | 2,580,379 | ||
| Total current liabilities | 3,435,683 | 3,671,235 | ||
| Preferred stock, 0.01 par value 20,000,000 shares authorized series b convertible preferred stock 1,543,158 shares designated, 1,398,158 shares issued and outstanding at september 30, 2025 and december 31, 2024 | 13,982 | 13,982 | ||
| Common stock, 0.0001 par value 75,000,000 shares authorized 7,978,117 and 6,919,919 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 797 | 797 | ||
| Total liabilities | - | 3,671,235 | ||
| Additional paid-in capital | 168,905,254 | 168,505,322 | ||
| Accumulated deficit | -166,713,054 | -163,674,777 | ||
| Total stockholders equity | 2,206,979 | 4,845,324 | ||
| Total liabilities and stockholders equity | 5,642,662 | 8,516,559 | ||
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)